Giovanni Battista Vigna
Overview
Explore the profile of Giovanni Battista Vigna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DErasmo L, Gallo A, Cefalu A, Di Costanzo A, Saheb S, Giammanco A, et al.
Orphanet J Rare Dis
. 2021 Sep;
16(1):381.
PMID: 34496902
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the...
2.
Matarazzo L, Ragnoni V, Malaventura C, Leon A, Colavito D, Vigna G, et al.
JIMD Rep
. 2020 Jul;
54(1):25-31.
PMID: 32685347
Glycerol-3-phosphate dehydrogenase 1 deficiency is a rare autosomal recessive disorder caused by mutations in the gene (GPD1; OMIM*138420). Very few cases are reported in literature. It usually manifests in early...
3.
Cervellati C, Vigna G, Trentini A, Sanz J, Zimetti F, Dalla Nora E, et al.
Atherosclerosis
. 2019 Apr;
285:64-70.
PMID: 31029939
Background And Aims: Epidemiological data showing that high-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular disease have led to the idea that cholesterol contained in this lipoprotein may be...
4.
Passaro A, Vigna G, Romani A, Sanz J, Cavicchio C, Bonaccorsi G, et al.
Oxid Med Cell Longev
. 2018 Dec;
2018:1752940.
PMID: 30524650
Paraoxonase-1 (PON1) and lipoprotein phospholipase A2 (Lp-PLA2) may exert an important protective role by preventing the oxidative transformation of high- and low-density lipoproteins (HDL and LDL, respectively). The activity of...
5.
DErasmo L, Cefalu A, Noto D, Giammanco A, Averna M, Pintus P, et al.
Adv Ther
. 2017 Apr;
34(5):1200-1210.
PMID: 28432645
Introduction: Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for...
6.
Soresi M, Noto D, Cefalu A, Martini S, Vigna G, Fonda M, et al.
Acta Diabetol
. 2012 Jun;
50(2):241-9.
PMID: 22684314
Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for...
7.
Vigna G, Fellin R
Expert Opin Pharmacother
. 2010 Oct;
11(18):3041-52.
PMID: 20958118
Importance Of The Field: Lipid-modifying drugs are therapeutic options that have been shown to reduce the biological and clinical burden related to atherosclerosis; they can be used to correct minor...
8.
Vigna G, Zuliani G, Fellin R
Eur J Intern Med
. 2010 May;
21(3):e19.
PMID: 20493406
No abstract available.
9.
Vigna G, Fellin R
Ital Heart J
. 2004 Feb;
4 Suppl 7:4S-12S.
PMID: 14983742
Epidemiological studies identified several risk factors as cardiovascular disease correlates, including smoking, obesity, hypertension, diabetes, and increased plasma lipids. High blood cholesterol, and in particular LDL cholesterol levels, represents a...